Later with the CANVAS (45), DECLARE-TIMI 58 (46), and CREDENCE (47) trials, the SGLT2 inhibitors canagliflozin and dapagliflozin were also shown to decrease the risk of cardiovascular death and renal failure. This evidence concerns the gene SLC5A2 and acute kidney injury.